金石亚药：双氯芬酸钠缓释片通过仿制药一致性评价

Core Viewpoint - Jinsiyaya Pharmaceutical (300434) announced that its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-Release Tablets (0.1g specification), which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - Jinsiyaya Pharmaceutical's subsidiary, Zhejiang Deer Pharmaceutical, has successfully obtained a drug supplement application approval notice [1] - The approved product is Diclofenac Sodium Sustained-Release Tablets, indicating a significant milestone in the company's product portfolio [1] - The approval reflects the company's commitment to meeting regulatory standards and enhancing its market position in the pharmaceutical industry [1]